| abstract |
The present disclosure describes a CD3 binding molecule that specifically binds to CD3, such as a monospecific binding molecule that specifically binds to CD3 and a multispecific binding molecule (MBM) that specifically binds to CD3 and tumor-related antigens. Provided are a conjugate containing a CD3 binding molecule and a pharmaceutical composition containing the CD3 binding molecule and the conjugate. The present disclosure further provides a method of activating T cells using a CD3 binding molecule, a conjugate and a pharmaceutical composition in a subject, eg, a subject having a cancer or autoimmune disease. The present disclosure further provides a method of producing a CD3 binding molecule by culturing the recombinant host cell modified to express the CD3 binding molecule and the host cell under conditions in which the CD3 binding molecule is expressed. |